A Phase 2 interventional study of Recombinant human C1 inhibitor and Placebo in Hereditary Angioedema, sponsored by Pharming Technologies B.V.. Completed at 10 sites in 7 countries. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2017-12-08.
Sponsored by Pharming Technologies B.V. (part of Pharming Group N.V.) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. Complement C1 Inhibitor Protein · Angioedemas, Hereditary.
Among the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary, this one is the 9th largest by enrollment, is the only one that started in 2014, is one of 2 in phase 2, and was the 15th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →None of the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →
Complement C1 Inhibitor Protein: first FDA approval 2014 (Ruconest), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 13 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 10 · Phase 4 2
First in 2004; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 32 across the 17 interventional studies. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 17 have an industry lead sponsor. The 9 most frequent:
This study is registered under Pharming Technologies B.V., one of the names counted as Pharming Group N.V.. Under that name alone:
Pharming Technologies B.V. is the lead sponsor of 22 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Pharming Group N.V. has 8 studies filed under Angioedemas, Hereditary — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the efficacy of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of angioedema attacks in patients with HAE
Secondary Objective:
To evaluate the safety and immunogenicity of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of angioedema attacks in patients with HAE
Study Design:
This is a multi-center, randomized, double-blind, placebo-controlled, 3-period crossover study of rhC1INH in prophylaxis of angioedema attacks in patients with HAE.
Medical screening (clinical and laboratory parameters) will be performed and patient medical history specific to HAE attacks will be collected to assess eligibility. Each patient will receive three 4 week periods of treatment twice weekly.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients fulfilling the following criteria at Screening are eligible for participation in the study:
Exclusion Criteria:
Patients who meet any of the following criteria at Screening are to be excluded from study participation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
rhC1INH administered twice weekly
Biological: Recombinant human C1 inhibitor
rhC1INH administered once weekly
Biological: Recombinant human C1 inhibitor
Placebo (Saline) administered twice weekly
Other: Placebo
Drug pages: Complement C1 Inhibitor Protein · Conestat alfa · C1 esterase inhibitor (human)
Also known as: rhC1INH, Ruconest, Conestat alfa
Also known as: Saline
Number of HAE Attacks
Average number of HAE attacks normalized to a 28 day period
Time frame: 28 days
Number of Participants With Adverse Events
Number of participants that experienced Treatment Emergent Adverse Events observed in safety population
Time frame: 20 weeks
Percentage of Participants Achieving at Least 50% Reduction in Number of Attacks
Percentage of participants achieving at least 50% reduction in the number of attacks normalized to a 28-day period as compared to the placebo treatment period
Time frame: 28 days
Immunogenicity
Number of participants analyzed for neutralizing C1INH-specific antibodies and neutralizing rhC1INH-specific antibodies after confirmed anti-C1INH and anti rhC1INH IgM or IgG antibodies
Time frame: 20 weeks
| Milestone | Treatment Sequence A | Treatments Sequence B | Treatment Sequesce C | Treatment Sequence D | Treatment Sequence E | Treatment Sequence F |
|---|---|---|---|---|---|---|
| Started | 5 | 6 | 5 | 5 | 6 | 5 |
| Completed | 5 | 3 | 4 | 5 | 5 | 4 |
| Not completed | 0 | 3 | 1 | 0 | 1 | 1 |
Average number of HAE attacks normalized to a 28 day period
| attacks | rhC1INH Twice Weekly | rhC1INH Once Weekly | Placebo (Saline) Twice Weekly |
|---|---|---|---|
| Number of HAE Attacks | 2.74 (1.8 to 3.7) | 4.36 (3.1 to 5.6) | 7.18 (5.8 to 8.6) |
Number of participants that experienced Treatment Emergent Adverse Events observed in safety population
| Participants | rhC1INH Twice Weekly | rhC1INH Once Weekly | Placebo (Saline) Twice Weekly |
|---|---|---|---|
| Number of Participants With Adverse Events | 10 | 13 | 8 |
Percentage of participants achieving at least 50% reduction in the number of attacks normalized to a 28-day period as compared to the placebo treatment period
| percentage of participants | rhC1INH Twice Weekly | rhC1INH Once Weekly |
|---|---|---|
| Percentage of Participants Achieving at Least 50% Reduction in Number of Attacks | 74 (57 to 86) | 42 (26 to 59) |
Number of participants analyzed for neutralizing C1INH-specific antibodies and neutralizing rhC1INH-specific antibodies after confirmed anti-C1INH and anti rhC1INH IgM or IgG antibodies
| Participants | rhC1INH Twice Weekly | rhC1INH Once Weekly | Placebo (Saline) Twice Weekly |
|---|---|---|---|
| Immunogenicity | 0 | 0 | 0 |
Collected over 20 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rhC1INH Twice Weekly | — | 1/29 (3.4%) | 5/29 (17.2%) |
| rhC1INH Once Weekly | — | 0/29 (0%) | 7/29 (24.1%) |
| Placebo (Saline) Twice Weekly | — | 0/28 (0%) | 2/28 (7.1%) |
| Event | rhC1INH Twice Weekly | rhC1INH Once Weekly | Placebo (Saline) Twice Weekly |
|---|---|---|---|
| PhimosisCongenital, familial and genetic disorders | 1/29 | 0/29 | 0/28 |
| Event | rhC1INH Twice Weekly | rhC1INH Once Weekly | Placebo (Saline) Twice Weekly |
|---|---|---|---|
| HeadacheNervous system disorders | 5/29 | 2/29 | 0/28 |
| NasopharyngitisInfections and infestations | 0/29 | 3/29 | 2/28 |
| AnxietyPsychiatric disorders | 0/29 | 2/29 | 0/28 |
Population is intention to treat (ITT) population
| Age, Categorical(Participants) | All Study Participants |
|---|---|
| <=18 years | 1 |
| Between 18 and 65 years | 28 |
| >=65 years | 3 |
| Age, Continuous(years) | All Study Participants |
|---|---|
| Mean | 46 (17 to 74) |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 26 |
| Male | 6 |
| Region of Enrollment(participants) | All Study Participants |
|---|---|
| Canada | 2 |
| Czech Republic | 2 |
| Romania | 6 |
| United States | 7 |
| Macedonia, The Former Yugoslav Republic of | 8 |
| Italy | 1 |
| Serbia | 2 |
| Israel | 4 |
The record gives a start of Dec 2014, a primary completion of May 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2017, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Complement C1 Inhibitor Protein · Conestat alfa · C1 esterase inhibitor (human)